 
	 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society on Intensive Care Medicine (ESICM). Eur J HeartFail. 2008;10 (10):933–989. 
	 Фомин И. В. Артериальная гипертония в Российской Федерации – последние 10 лет. Что дальше? Сердце. 2007;6 (3):1–6. 
	 Фомин И. В. Эпидемиология хронической сердечной недостаточности в Российской Федерации. В кн.: Хроническая сердечная недостаточность [Агеев Ф. Т. и соавт.] – М.: ГЭОТАР-Медиа, 2010. – c. 7–77. 
	 Cleland J.G., Swedberg K., Follath F. et al. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24 (5):442–463. 
	 Lam C.S.P., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail 2014;16:1049–1055. 
	 Щербинина Е.В., Бадин Ю.В., Вайсберг А.Р., и.др. Динамика этиологических причин формирования ХСН в репрезентативной выборке Нижегородской области за 9 лет наблюдения (1998–2007 гг.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2007 год» – М., 2007. – с. 38. 
	 Фомин И. В., Бадин Ю. В., Егорова И. С., Щербинина Е. В. Гендерные различия в распространенности сердечно-сосудистых заболеваний (данные когортного исследования репрезентативной выборки Нижегородской области 1998–2002 гг.). Проблемы женского здоровья. 2006;1 (1):37–40. 
	 Ho K.K., Pinsky J.L., Kannel W.B., Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(4 Suppl A):6A-13A. 
	 Owan T.E.,Hodge D.O.,Herges R.M.,Jacobsen S.J.,Roger V.L.,Redfield M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251–259. 
	 Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J2012;33:1750–1757. 
	 Hogg K., Swedberg K., McMurray J. Heart Failure with preserved left ventricular systolic function. Epidemiology, Clinical Characteristics, and Prognosis. J Am Coll Cardiol. 2004;43 (3):317–327. 
	 АгеевФ. Т. Влияниесовременныхмедикаментозныхсредствнатечениезаболевания «качествожизни» ипрогнозбольныхсразличнымистадиями хронической сердечной недостаточности. Автореф. Дисс. Докт., Москва, 1997. 
	 Терещенко С.Н., Жиров И.В., Нарусов О.Ю., Мареев Ю.В., Затейщиков Д.А., Осмоловская Ю.Ф., Овчинников А.Г., Самко А.Н., Насонова С.Н., Стукалова О.В., Саидова М.А., Скворцов А.А., Шария М.А., Явелов И.С.  Диагностика и лечениехронической и острой сердечной недостаточности. Кардиологическийвестник, 2016; № 2:3-33. 
	 McMurray J. Clinical practice. Systolic heart failure. N Engl J Med. 2010;362 (3):228–238. 
	 Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306 (15):1669–1678. 
	 Dunlay S.M., Redfield M.M., Weston S.A. et al. Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol. 2009;54 (18):1695–1702. 
	 Senni M., Gavazzi A., Oliva F., at al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Intern J Cardiol 2014;173:163-9. 
	 Cowie M.R., Fox K.F., Wood D.A. et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J. 2002;23 (11):877–885. 
	 McAlister F.A., Teo K.K., Taher M. et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999;138 (1 Pt 1):87–94. 
	 Беленков Ю.Н., Овчинников А.Г., Агеев Ф.Т., Сербул В.М. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы.  Кардиоваскулярная терапия и профилактика 2008; №2:98-108. 
	 Овчинников А.Г., Агеев Ф.Т., Свирида О.Н.  Патогенетический подход к терапии пациентов с хронической сердечной недостаточностью и сохраненной систолической функцией левого желудочка. Кардиологический вестник 2011;№1: 33-39. 
	 Pocock S.J., Wang D., Pfeffer M.A. et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27 (1):65–75. 
	 Komajda M., Carson P.E., Hetzel S. et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail. 2011;4 (1):27–35. 
	 Ketchum E.S., Levy W.C. Establishing prognosis in heart failure: a multimarker approach. Prog Cardiovasc Dis. 2011;54 (2):86–96. 
	 Ho K.K., Anderson K.M., Kannel W.B. et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.Circulation. 1993;88 (1):107–115. 
	 Даниелян М. О. Прогноз и лечение хронической сердечной недостаточности (данные 20-и летнего наблюдения). Автореф. дис. канд. мед.наук. Москва. 2001. 
	 Бадин Ю. В., Фомин И. В. Выживаемость больных ХСН в когортной выборке Нижегородской области (данные 1998–2002 годов.). Всероссийская конференция ОССН: «Сердечная недостаточность, 2005 год» – М., 2005. – с. 31–32. 
	 WedelH., McMurrayJ.J., LindbergMetal. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal proB-type natriuretic peptide. Eur J Heart Fail. 2009;11 (3):281–291. 
	 Allen L.A., Felker G.M., Pocock S. et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11 (2):170–177. 
	 Jackson C.E., Solomon S.D., Gerstein H.C. et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009;374 (9689):543–550. 
	 Felker G.M., Allen L.A., Pocock S.J. et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007;50(1):40–47. 
	 БеленковЮ. Н., ФоминИ. В., МареевВ. Ю. идр. ПервыерезультатыРоссийскогоэпидемиологического исследования по ХСН.Журнал Сердечная Недостаточность 2003;4 (1):26–30. 
	 Агеев Ф. Т., Даниелян М. О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА–О–ХСН). Журнал Сердечная Недостаточность 2004;5 (1):4–7. 
	 Агеев Ф. Т., Беленков Ю. Н., Фомин И. В. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная Недостаточность 2006;7 (1): 112–115. 
	 Davie P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use? QJM 1997;90:335–339. 
	 Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs FDR. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009;13:1–207, iii. 
	 Oudejans I., Mosterd A., Bloemen J.A., Valk M.J., Van Velzen E., Wielders J.P., Zuithoff N.P., Rutten F.H., Hoes A.W. Clinical evaluation of geriatric outpatients with suspected heart failure: value of symptoms, signs, and additional tests. Eur J Heart Fail 2011;13:518–527. 
	 Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006;11:95–107. 
	 Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons KGM, Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:2865–2873. 
	 Roberts E., Ludman A.J., Dworzynski K., Al-Mohammad A., Cowie M.R., McMurray J.J.V., Mant J. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015;350:h910. 
	 Zaphiriou A., Robb S., Murray-Thomas T., Mendez G., Fox K., McDonagh T., Hardman S.M.C., Dargie H.J., Cowie M.R. The diagnostic accuracy of plasma BNP and NTpro мозговой натрийуретический пептид in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005;7:537–541. 
	 Fuat A., Murphy J.J., Hungin A.P.S., Curry J., Mehrzad A.A., Hetherington A., Johnston J.I., Smellie W.S.A., Duffy V., Cawley P. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 2006;56:327–333. 
	 Yamamoto K., Burnett J.C., Bermudez E.A., Jougasaki M., Bailey K.R., Redfield M.M. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000;6:194–200. 
	 Cowie M.R., Struthers A.D., Wood D.A., Coats A.J., Thompson S.G., Poole-Wilson P.A., Sutton G.C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349–1353. 
	 Krishnaswamy P., Lubien E., Clopton P., Koon J., Kazanegra R., Wanner E., Gardetto N., Garcia A., DeMaria A., Maisel A.S. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001;111:274–279. 
	 Kelder J.C., Cramer M.J., Verweij W.M., Grobbee D.E., Hoes A.W.Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. JCardFail 2011;17:729–734 
	 van Riet E.E.S., Hoes A.W., Limburg A., Landman M.A.J., van der Hoeven H., Rutten F.H. Prevalence of unrecognized heart failure in older persons with shortness ofbreath on exertion. Eur J Heart Fail 2014;16:772–777. 
	 Kelder J.C., Cramer M.J., van Wijngaarden J., van Tooren R., Mosterd A., Moons K.G.M., Lammers J.W., Cowie M.R., Grobbee D.E., Hoes A.W. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011;124:2865–2873. 
	 Davie A.P., Francis C.M., Love M.P., Caruana L., Starkey I.R., Shaw T.R., Sutherland G.R., McMurray J.J. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ 1996;312:222. 
	 Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002;112:437–445. 
	 Paulus W.J., Tschope C., Sanderson J.E., Rusconi C., Flachskampf F.A., Rademakers F.E., Marino P., Smiseth O.A., De Keulenaer G., Leite-Moreira A.F., Borbely A., Edes I.,Handoko M.L., Heymans S., Pezzali N., Pieske B., Dickstein K., Fraser A.G.,Brutsaert D.L. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539–2550. 
	 Marwick T.H., Raman S.V., Carrio? I., Bax J.J. Recent developments in heart failure imaging. JACC Cardiovasc Imaging 2010;3:429–439. 
	 Dokainish H., Nguyen J.S., Bobek J., Goswami R., Lakkis N.M. Assessment of the American Society of Echocardiography-European Association of Echocardiography guidelines for diastolic function in patients with depressed ejection fraction: an echocardiographic and invasive haemodynamic study. Eur J Echocardiogr 2011; 12:857–864. 
	 Kirkpatrick J.N., Vannan M.A., Narula J., Lang R.M. Echocardiography in heart failure: applications, utility, and new horizons. J Am Coll Cardiol 2007;50:381–396. 
	 Nagueh S.F., Bhatt R., Vivo R.P., Krim S.R., Sarvari S.I., Russell K., Edvardsen T., Smiseth O.A., Estep J.D. Echocardiographic evaluation of hemodynamics in patients with decompensated systolic heart failure. Circ Cardiovasc Imaging 2011;4: 220–227. 
	 Caballero L., Kou S., Dulgheru R., Gonjilashvili N., Athanassopoulos G.D., Barone D., Baroni M., Cardim N., Gomez de Diego J.J., Oliva M.J., Hagendorff A., Hristova K., Lopez T., Magne J., Martinez C., de la Morena G., Popescu B.A., Penicka M.,Ozyigit T., Rodrigo Carbonero J.D., Salustri A., Van De Veire N., Von Bardeleben R.S., Vinereanu D., Voigt J-U, Zamorano J.L., Bernard A., Donal E., Lang R.M., Badano L.P., Lancellotti P. Echocardiographic reference ranges for normal cardiac Doppler data: results from the NORRE Study. Eur Heart J Cardiovasc Imaging 2015;16:1031–1041. 
	 Garbi M., McDonagh T., Cosyns B., Bucciarelli-Ducci C., Edvardsen T., Kitsiou A., Nieman K., Lancellotti P. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging 2015;16: 147–153. 
	 Lang R.M., Badano L.P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F.A., Foster E., Goldstein S.A., Kuznetsova T., Lancellotti P., Muraru D., Picard M.H., Rietzschel E.R., Rudski L., Spencer K.T., TsangW., Voigt J-U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16: 233–270. 
	 Gimelli A., Lancellotti P., Badano L.P., Lombardi M., Gerber B., Plein S., Neglia D., Edvardsen T., Kitsiou A., Scholte AJHA, Schroder S., Cosyns B., Gargiulo P., Zamorano J.L., Perrone-Filardi P. Non-invasive cardiac imaging evaluation of patients with chronic systolic heart failure: a report from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J 2014;35:3417–3425. 
	 Voigt J-U, Pedrizzetti G., Lysyansky P., Marwick T.H., Houle H., Baumann R., Pedri S., Ito Y., Abe Y., Metz S., Song J.H., Hamilton J., Sengupta P.P., Kolias T.J., d’Hooge J., Aurigemma G.P., Thomas J.D., Badano L.P. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ ASE/Industry Task Force to standardize deformation imaging. Eur.HeartJ. Cardiovasc. Imaging 2015;16:1–11. 
	 Cohen G.I., Pietrolungo J.F., Thomas J.D., Klein A.L. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996;27:1753–1760. 
	 Gilman G., Nelson T.A., Hansen W.H., Khandheria B.K., Ommen S.R. Diastolic function:a sonographer’s approach to the essential echocardiographic measurements of left ventricular diastolic function. J Am Soc Echocardiogr 2007;20:199–209. 
	 Nagueh S.F., Appleton C.P., Gillebert T.C., Marino P.N., Oh J.K., Smiseth O.A.,Waggoner A.D., Flachskampf F.A., Pellikka P.A., Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165–193. 
	 Nishimura R.A., Appleton C.P., RedfieldM.M., Ilstrup D.M., Holmes D.R., Tajik A.J. Noninvasive doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study. J Am Coll Cardiol 1996;28:1226–1233. 
	 Ommen S.R., Nishimura R.A., Appleton C.P., Miller F.A., Oh J.K., Redfield M.M., Tajik A.J. Clinical utility of Doppler echocardiography and tissue doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Dopplercatheterization study. Circulation 2000;102:1788–1794 
	 HawkinsN.M., Petrie M.C., Jhund P.S., ChalmersG.W., Dunn F.G., McMurray J.J.V. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009;11:130–139. 
	 Thomas J.T., Kelly R.F., Thomas S.J., Stamos T.D., Albasha K., Parrillo J.E., Calvin J.E. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure.Am J Med 2002;112:437–445. 
	 Windecker S., Kolh P., Alfonso F., Collet J-P., Cremer J., Falk. V, Filippatos G., Hamm C., Head S.J., Juni P., Kappetein A.P., Kastrati A., Knuuti J., Landmesser U., Laufer G., Neumann F-J., Richter D.J., Schauerte P., Sousa Uva M., Stefanini G.G., Taggart D.P., Torracca L., Valgimigli M., Wijns W. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619. 
	 Montalescot G., Sechtem U., Achenbach S., Andreotti F., Arden C., Budaj A., Bugiardini R., Crea F., Cuisset T., Di Mario C., Ferreira J.R., Gersh B.J., Gitt A.K., Hulot J-S., Marx N., Opie L.H., Pfisterer M., Prescott E., Ruschitzka F., Sabate? M., Senior R., Taggart D.P., van der Wall E.E., Vrints C.J.M., Zamorano J.L.,Baumgartner H., Bax J.J., Bueno H., Dean V., Deaton C., Erol C., Fagard R., Ferrari R., Hasdai D., Hoes A.W., Kirchhof P., Knuuti J., Kolh P., Lancellotti P.,Linhart A., Nihoyannopoulos P., Piepoli M.F., Ponikowski P., Sirnes P.A., Tamargo J.L., Tendera M., Torbicki A., Wijns W., Windecker S., Valgimigli M.,Claeys M.J., Donner-Banzhoff N., Frank H., Funck-Brentano C., Gaemperli O., Gonzalez-Juanatey J.R., Hamilos M., Husted S., James S.K., Kervinen K.,Kristensen S.D., Maggioni A. Pietro, Pries A.R., Romeo F., Ryde?n L., Simoons M.L., Steg P.G., Timmis A., Yildirir A. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949–3003. 
	 Roffi M., Patrono C., Collet J-P., Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2015; ehv320. 
	 Beller G.A., Heede R.C. SPECT imaging for detecting coronary artery disease and determining prognosis by noninvasive assessment of myocardial perfusion and myocardial viability. J Cardiovasc Transl Res 2011;4:416–424. 
	 Sicari R., Nihoyannopoulos P., Evangelista A., Kasprzak J., Lancellotti P., Poldermans D., Voigt J.U., Zamorano J.L. Stress Echocardiography Expert Consensus Statement—Executive Summary: European Association of Echocardiography (EAE) (a registered branch of the ESC). Eur Heart J 2009;30:278–289. 
	 Garnier F., Eicher J-C., Jazayeri S., Bertaux G., Bouchot O., Aho L-S., Wolf J-E., Laurent G. Usefulness and limitations of contractile reserve evaluation in patients with low-flow, low-gradient aortic stenosis eligible for cardiac resynchronization therapy. Eur J Heart Fail 2014;16:648–654 
	 Allman K.C., Shaw L.J., Hachamovitch R., Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39: 1151–1158. 
	 Ling L.F., Marwick T.H., Flores D.R., Jaber W.A., Brunken R.C., Cerqueira M.D., Hachamovitch R. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6:363–372. 
	 Bonow R.O., Maurer G., Lee K.L., Holly T.A., Binkley P.F., Desvigne-Nickens P., Drozdz J., Farsky P.S., Feldman A.M., Doenst T., Michler R.E., Berman D.S.,Nicolau J.C., Pellikka P.A, Wrobel K., Alotti N., Asch F.M., Favaloro L.E., She L., Velazquez E.J., Jones R.H., Panza J.A. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617–1625. 
	 Gonzalez J.A., Kramer C.M. Role of imaging techniques for diagnosis, prognosis and management of heart failure patients: cardiac magnetic resonance. Curr Heart Fail Rep 2015;12:276–283. 
	 Hundley W.G., Bluemke D.A., Finn J.P., Flamm S.D., Fogel M.A., Friedrich M.G., Ho V.B., Jerosch-Herold M., Kramer C.M., Manning W.J., Patel M., Pohost G.M., Stillman A.E., White R.D., Woodard P.K., Harrington R.A., Anderson J.L., Bates E.R., Bridges C.R., Eisenberg M.J., Ferrari V.A., Grines C.L., Hlatky M.A., Jacobs A.K., Kaul S., Lichtenberg R.C., Lindner J.R., Moliterno D.J., Mukherjee D., Rosenson R.S., Schofield R.S., Shubrooks S.J., Stein J.H., Tracy C.M., Weitz H.H., Wesley D.J. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the Аmerican college of cardiology foundation task force on expert consensus documents. Circulation 2010;121:2462–2508. 
	 Moon J.C., Messroghli D.R., Kellman P., Piechnik S.K., Robson M.D., Ugander M., Gatehouse P.D., Arai A.E., Friedrich M.G., Neubauer S., Schulz-Menger J., Schelbert E.B. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson 2013;15:92. 
	 Yoshida A., Ishibashi-Ueda H., Yamada N., Kanzaki H., Hasegawa T., Takahama H.,Amaki M., Asakura M., Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. EurJHeartFail 2013;15:166–175. 
	 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVDinvestigators. N Engl J Med. 1991;325 (5):293–302. 
	 Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987;316 (23):1429–1435. 
	 Garg R., Yusuf S., for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure JAMA. 1995;273 (18):1450–1456. 
	 Pfeffer M.A., Braunwald E., Moye L.A. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement Trial. The SAVE Investigators. N Engl J Med. 1992;327 (10):669–677. 
	 Kober L., Torp-Pedersen C., Carlsen J.E. et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333 (25):1670–1676. 
	 Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342 (8875):821–828. 
	 Packer M., Poole-Wilson P.A., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., Ryd?n L., Thygesen K., Uretsky B.F. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999 Dec 7;100(23):2312-8. 
	 Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med. 1992;327(10):685–691. 
	 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized  trial. Lancet 1999;353 (9146):9–13. 
	 MERIT-HF Study Group. Effects of metoprolol CR / XL in chronic heart failure: Metoprolol CR / XL Randomized International Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353(9169):2001–2007. 
	 Packer M., Bristow M.R., Cohn J.N. et al, for the U. S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334 (21):1349–1355. 
	 Packer M., Coats A.J., Fowler M.B. et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. 
	 Flather M.D., Shibata M.C., Coats A.J.et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26 (3):215–225. 
	 Poole – Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362(9377):7–13. 
	 Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357:1385-1390. 
	 Gattis W.A., O’Connor C.M., Leimberger J.D. et al. Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. Am J Cardiol. 2003;91 (2):169–174. 
	 Jondeau G., Neuder Y., Eicher J.C. et al. B-CONVINCED: Betablocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30 (18):2186–2192. 
	 Pitt B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341 (10):709–717. 
	 Zannad F., McMurray J.J., Krum H. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364 (1):11–21. 
	 Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348 (14):1309–1321. 
	 Pitt B., White H., Nicolau J. et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46 (3):425–431. 
	 Pitt B., Gheorghiade M., Zannad F. et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <or=30 %. Eur J Heart Fail. 2006;8 (3):295–301. 
	 Juurlink D.N., Mamdani M.M., Lee D.S. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351 (6):543–551. 
	 Faris R., Flather M., Purcell H., Henein M., Poole-Wilson P., Coats A.. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials. Int J Cardiol 2002;82:149–158. 
	 Faris R.F., Flather M., Purcell H., Poole-Wilson P.A., Coats A.J. Diuretics for heart failure.Cochrane Database Syst Rev 2012;2:CD003838. 
	 Dormans T.P., van Meyel J.J., Gerlag P.G. et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28 (2):376–382. 
	 Vargo D.L., Kramer W.G., Black P.K. et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther.1995;57 (6):601–609. 
	 Patterson J.H., Adams K.F. Jr, Applefeld M.M. et al. for the Torаsemide Investigators Group. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994;14 (5):514–521. 
	 Brater D. Torasemid: pharmacokinetic and clinical efficacy. Eur J Heart Fail. 2001;3 (Suppl G): 19–24. 
	 Cosin J., Diez J., Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4 (4):507–513 
	 Fortuno A., Muniz P., Ravassa S. et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension.1999;34 (1):138–143. 
	 Yamato M., Sasaki T., Honda K. et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J. 2003;67 (5):384–390. 
	 McMurray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L.,Shi V.C., Solomon S.D., Swedberg K., Zile M.R., PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004. 
	 Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril,or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349 (20):1893–1906. 
	 Granger C.B., McMurray J.J., Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM–Alternative trial. Lancet. 2003;362 (9386):772–776. 
	 Cohn J.N., Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med.2001;345 (23):1667–1675. 
	 Maggioni A.Р., Anand I., Gottlieb S.O. et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme inhibitors J Am Coll Cardiol. 2002;40 (8):1414–1421. 
	 McMurray J.J., Ostergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced leftventricular systolic function taking angiotensin-convertingenzyme inhibitors: the CHARM–Added trial. Lancet. 2003;362 (9386):767–771. 
	 Konstam M.A., Neaton J.D., Dickstein K. et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009;374 (9704):1840–1848. 
	 Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376 (9744):875–885. 
	 Digoxin"s effect on mortality and hospitalization in heart failure: implications of the DIG study. Digitalis Investigation Group. Cleve Clin J Med. 1997 May;64(5):234-7. 
	 Gheorghiade M., Fonarow G.C., van Veldhuisen D.J. et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013;34 (20):1489–1497. 
	 Jorge E., Baptista R., Martins H. et al. Digoxin in advanced heart failure patients: a question of rhythm. Rev Port Cardiol. 2013;32 (4):303–310. 
	 Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15 (5):551–559. 
	 Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–878. 
	 Adams K.F., Patterson J.H., Gattis W.A. et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46 (3):497–504. 
	 The GISSI-HF investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic hear